<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> Inc. Announces Phase 1 Study Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Cocrystal Pharma Inc. has announced positive results from a Phase 1 clinical study of its oral, direct-acting pan-viral inhibitor CDI-988. The study, which was randomized, double-blinded, and placebo-controlled, demonstrated that all doses of CDI-988, ranging from 100 mg to 1200 mg, were well tolerated. These findings were presented at the 2025 Military Health System Research Symposium. CDI-988 is being developed as a potential prophylaxis and treatment for norovirus, addressing a critical unmet medical need due to the lack of approved treatments or vaccines for the virus. Cocrystal Pharma plans to initiate a Phase 1b study with norovirus-infected healthy subjects later this year. The development of CDI-988 is supported by Cocrystal's proprietary structure-based platform technology, aimed at creating novel broad-spectrum antivirals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022153), on August 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.